Earlier Liver Cancer Diagnosis May Soon Be Possible, MIT Study Finds
Researchers at MIT have developed a method that could dramatically transform liver cancer diagnosis by identifying cellular changes linked to cancer risk years before tumors actually develop. The approach, published in the Proceedings of the National Academy of Sciences, involves sequencing the DNA of liver cells to detect a distinctive pattern of mutations caused by exposure to aflatoxin, a fungal toxin widely present in food supplies across parts of Southeast Asia and sub-Saharan Africa.
Aflatoxin is estimated to cause up to 80 percent of liver cancer cases in those regions, where it commonly contaminates dietary staples such as corn and peanuts. In countries like the United States and Europe, where food safety regulation limits exposure, the risk is considerably lower. However, for hundreds of millions of people in high exposure regions, the ability to detect pre-cancerous DNA changes early could represent a life saving advance in liver cancer diagnosis.
How the DNA Fingerprint Works
The core innovation involves identifying a specific mutational signature, or fingerprint, left in liver cell DNA following aflatoxin exposure. Senior author John Essigmann of MIT described the approach as measuring prior exposure to a cancer causing agent through the genetic record it leaves behind.
Aflatoxin typically causes liver cancer by converting the DNA base guanine to thymine. The MIT team found that this mutation occurs with particular frequency in CGC sequences, where guanine is flanked on both sides by cytosine. Approximately 25 percent of the mutations in aflatoxin exposed cells occurred in this specific pattern, a signature distinct enough to serve as a reliable indicator of prior carcinogen exposure.
To detect these mutations, the researchers used a genome sequencing technique developed at the University of Washington that is 1,000 to 10,000 times more accurate than conventional DNA sequencing. The method barcodes both strands of double stranded DNA and recombines the data, allowing researchers to distinguish genuine rare mutations from the copying errors that undermine standard sequencing approaches. This level of precision is essential when looking for mutations that occur in approximately 1 in 10 million to 100 million DNA base pairs.
From Animal Studies to Human Relevance
In the study, mice were exposed to a single dose of aflatoxin shortly after birth. All eventually developed liver cancer. The researchers sequenced DNA from the resulting tumors and also from liver cells removed just 10 weeks after exposure, well before any tumors had formed. The distinctive mutational fingerprint was already clearly present at 10 weeks, confirming that the signature emerges long before cancer develops.
The team then compared this mutational profile against genetic sequences from liver tumors in more than 300 patients from around the world. The mouse mutation pattern closely matched the profiles of 13 patients, primarily from sub-Saharan Africa and Asia, who were believed to have had dietary aflatoxin exposure. This cross species validation strengthens the case for using this approach as the basis for a practical liver cancer diagnosis tool in human populations.
What a Future Test Could Look Like
The MIT team is now working toward a simpler, more accessible version of this detection approach, potentially a blood test that could be screened for the aflatoxin mutational profile. Patients who tested positive would be candidates for regular liver monitoring, enabling the early identification and surgical removal of tumors before they progress to advanced stages.
Beyond liver cancer diagnosis, the researchers see broader applications. The same framework could be used to generate mutational profiles for other carcinogens, building a library of DNA fingerprints that identify exposure to specific cancer causing agents. The team also plans to investigate other liver carcinogens, including dimethylnitrosamine, a chemical byproduct recently found as a contaminant in some drinking water sources.
The research also opens possibilities for testing cancer protective interventions. Scientists in China are already exploring whether compounds found in broccoli sprout tea can block the pathway leading to aflatoxin induced DNA mutations. Drugs such as oltipraz are similarly under investigation for their potential to prevent this form of carcinogen driven genetic damage.
For a comprehensive overview of liver cancer, its risk factors and current diagnostic approaches, the Mayo Clinic provides an accessible and thorough resource.
Clinical Research and Oncology Innovation
Advances like this one depend on a robust pipeline of clinical investigation. Moving from a laboratory finding to a validated diagnostic test requires trials that test accuracy, reproducibility, and real world utility across diverse patient populations.
FOMAT supports oncology clinical research across a national network of investigator sites, contributing to the development of next generation tools for cancer detection and treatment. To explore active oncology studies, visit our patient active studies page. For more research and health insights, visit the FOMAT blogs and updates.